Asthma is usually characterized by chronic airway inflammation and symptoms of wheezing, shortness of breath, chest tightness and/or cough. Exercise, environmental/occupational exposures, and/or viral respiratory infections can trigger symptoms. The long-term goals of asthma management are to achieve good symptom control, minimize future risk of exacerbations, minimize fixed airflow limitation, and minimize side-effects of treatment.
People with non-eosinophilic asthma may be eligible to join this research study of an investigational medication for the condition. Eligible participants will receive compensation for study-related time, as well as study-related exams at no cost.
- Must be age 18 or older
- Must have poorly controlled asthma despite the use of an inhaled corticosteroid (ICS) and LABA for at least 3 months
- Must have had at least one asthma exacerbation in the past 12 months
- Must NOT have pulmonary disease other than asthma
- Must NOT smoke
- Will receive compensation for study-related time
- Do not need insurance to join this study
For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.
You can talk to a Meridian enrollment specialist about this study by calling (402) 934-7563 (NE) or (912) 623-2240 (VA).
Submit your information
Founded in 1999 in Omaha, NE, Meridian studies the safety and effectiveness of new medicines, devices, and treatments. Its mission is to enrich lives by providing quality, compassionate care to patients and unparalleled clinical research services. Clinical studies help scientists develop life-changing medicines, but it starts with you — participation makes it all possible. For more than 20 years, thousands of patients have trusted Meridian because of our focus on creating a positive patient experience.